Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,343,026
  • Shares Outstanding, K 53,166
  • Annual Sales, $ 46,700 K
  • Annual Income, $ -191,000 K
  • 60-Month Beta 2.05
  • Price/Sales 48.77
  • Price/Cash Flow N/A
  • Price/Book 3.15
Trade ARVN with:

Options Overview Details

View History
  • Implied Volatility 82.46% ( +3.00%)
  • Historical Volatility 86.55%
  • IV Percentile 95%
  • IV Rank 73.37%
  • IV High 91.99% on 05/12/22
  • IV Low 56.20% on 04/05/22
  • Put/Call Vol Ratio 12.00
  • Today's Volume 13
  • Volume Avg (30-Day) 606
  • Put/Call OI Ratio 1.16
  • Today's Open Interest 10,363
  • Open Int (30-Day) 9,081

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.02
  • Number of Estimates 11
  • High Estimate -0.12
  • Low Estimate -1.64
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +0.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.41 +19.33%
on 05/09/22
66.98 -33.35%
on 04/21/22
-21.58 (-32.59%)
since 04/20/22
3-Month
37.41 +19.33%
on 05/09/22
75.39 -40.79%
on 04/05/22
-24.38 (-35.32%)
since 02/18/22
52-Week
37.41 +19.33%
on 05/09/22
108.46 -58.84%
on 07/29/21
-19.31 (-30.20%)
since 05/20/21

Most Recent Stories

More News
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ARVN : 44.64 (+1.29%)
NVAX : 53.42 (-8.57%)
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 44.64 (+1.29%)
Arvinas to Present at Upcoming Investor Conferences

NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 44.64 (+1.29%)
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.

RHHBY : 41.1100 (+0.91%)
EPZM : 0.5103 (-2.84%)
ADAP : 1.6400 (-1.80%)
ARVN : 44.64 (+1.29%)
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

ADAP : 1.6400 (-1.80%)
ABUS : 2.44 (+4.27%)
AXSM : 31.65 (+0.44%)
ARVN : 44.64 (+1.29%)
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ARVN : 44.64 (+1.29%)
CLSD : 1.3800 (-4.83%)
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 44.64 (+1.29%)
Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.

VRTX : 258.59 (+1.23%)
AERI : 6.81 (-4.62%)
ABUS : 2.44 (+4.27%)
ARVN : 44.64 (+1.29%)
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the...

KYMR : 14.79 (-0.67%)
ARVN : 44.64 (+1.29%)
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable...

ARVN : 44.64 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 48.03
2nd Resistance Point 46.36
1st Resistance Point 45.22
Last Price 44.64
1st Support Level 42.41
2nd Support Level 40.74
3rd Support Level 39.60

See More

52-Week High 108.46
Fibonacci 61.8% 81.32
Fibonacci 50% 72.94
Fibonacci 38.2% 64.55
Last Price 44.64
52-Week Low 37.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar